CURIS INC — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Curis reported Q3 2026 net loss of $8.1M ($1.94/share) vs. $7.7M ($9.86/share) in Q3 2025; nine-month loss of $40.9M ($16.77/share) vs. $26.9M ($43.82/share) in 2025. The company raised ~$7.5M in October 2026 private placement; combined with $5.0M cash on-hand as of September 30, 2026, management expects to fund operations into Q1 2027. TakeAim CLL study enrolled 12 patients with initial data expected December 2026; TakeAim Lymphoma (PCNSL) registrational study reported 86% ORR in 7 BTKi-naive patients and 26% ORR in 39 BTKi-experienced patients as of July 2026.
Why this rating
Clinical progress on lead asset supports survival, but severe near-term cash burn ($8.1M/quarter ~32% of market cap) and runway into only Q1 2027 create imminent dilution/financing risk relative to $24.8M market value.
Price action (we called it neutral)
before filing · preread $0.44 ▼ 0.00% | at our read · unknown $0.45 | +10 min · unknown $0.45 ▲ 0.00% | +30 min · unknown $0.43 ▼ 3.82% | +1 hr · unknown $0.42 ▼ 5.39% | +4 hrs · unknown $0.43 ▼ 2.92% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.